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ABSTRACT 
Brain tumours are the most lethal type of cancer, which is difficult to manage due to the inherent suboptimal bioavailability of the chemotherapy 
agent at tumour sites, consequent of high levels of protection of physiological blood-brain barrier (BBB), blood tumour barrier (BTB) and blood-
cerebrospinal fluid barrier (CSF). Improving the permeability of these barriers would enhance the disease's clinical prognosis and promote patients' 
quality of life. To this end, scientists have conducted several studies to determine the most suitable route for CNS delivery. Most of which show that 
the nose-to-brain is proposed to be the most convenient, efficacious and clinically beneficial non-invasive means of delivering chemotherapeutic 
agents directly to the brain. Therefore, this study compares the therapeutic benefits of intranasal and other conventional brain delivery systems 
and further evaluates the clinical benefits of using different nanocarriers for brain tumour targeting. However, we surveyed the literature by 
conducting an in-depth search of the research keywords and their combinations in recognized scientific databases, primarily Science Direct, 
PubMed, Google Scholar, and Research Gate. Our findings have shown that the nose-to-brain delivery of chemotherapeutics is a breakthrough in 
bypassing the effects of BBB, BTB, and CSF barriers, improving the delivery of drugs to the brain for specific tumour targeting with desired clinical 
prognosis.  
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INTRODUCTION 
Edwin Smith was the first to discuss the central nervous system 
CNS's concept in his papyrus about 3,600 y ago [1, 2]. Later, 
about 1,300 BC, the Ebers’ papyrus described the concept of 
cancer and tumors [3]. Besides, Hippocrates identified some 
tumors in the crab’s legs and called them “karkinos,” in Greek 
words, meaning “crab/cancer,” in English [4]. The global brain 
cancer incidence is higher in men than in women, in developed 
than under-developed countries with the incidence and 
mortality rates of 3.4 and 2.5 par 100,000. Albania has the 
highest prevalence of 7.5 par 100,000 [5]. It accounts for 3% of 
all cancer globally [6]. Nevertheless, the significant risk factors 
are immune-imbalances, hormones, family history, smoking, 
alcoholism, in addition to radiation, and ageing [7]. 
Primarily, CNS tumors have been classified into; pituitary adenomas, 
gliomas, and primitive or vestibular neuroectodermal tumors, out of 
which ‘glioblastoma multiform’ (GBM) emerged as the most lethal 
type of CNS malignancy with 81% prevalence [8, 9] and 12–15 mo 
survival chance [10]. Moreover, the World Health Organization 
(WHO) graded the tumors into low-grade gliomas (grade I and II) 
and high-grade gliomas (grade III and IV), respectively [11]. 
Glioblastoma (high-grade glioma stage IV) is the most lethal type 
with less than a 5% survival rate [12], and more than 90% 
recurrence chances [13]. Nevertheless, the pattern of metastases 
and localization of glioblastoma malignancy remains unclear [14]. 
But, it shows dynamic changes in morphological and structural 
forms over time [15]. Understanding these concepts will 
significantly optimize the disease prognosis and increase the 
survival chances of the affected patients [16]. Henceforth, effective 
treatment of these malignancies is among the most challenging 
aspects of the pharmaceutical research field. Because, the blood-
brain barrier (BBB), blood tumor barrier (BTB) and 
immunoregulatory mechanisms have become the rate-limiting steps 
for delivering chemotherapeutic agents to CNS [17]. The 
contemporary management approaches including surgery, radiation 
therapy [18]. and Temozolomide (TMZ) have shown limited clinical 
benefits [19]. Bypassing the BBB through an invasive approach 
(using physical carriers) could compromise brain functions and 
induce neurotoxicity. Therefore, a non-invasive (carrier-free) 
approach could increase drug permeability across the BBB to the 
target tumor [20]. Hence, the study of advances that could enhance 
drug delivery across these barriers is highly needed[21]. The 
established literature have proved the effectiveness of 
chemotherapeutic agents when delivered via the nose-to brain route 
through olfactory and trigeminal nerves [22]. The clinical benefits of 
using intranasal delivery outweigh that of other routes [23]. As we 
discussed in (table 3). However, the molecule meant for brain 
targeting should be highly lipophilic non-ionized, less than 400 Da 
molecular weight, with an ionization constant range from 0.5 to 6.0 
at physiological PH [24]. Nonetheless, the aforementioned features 
alone are not enough to provide sufficient pharmacokinetic effects 
that could permit a molecule to cross BBB efficiently [25]. Although, 
mucociliary clearance, enzymatic degradation of proteins and 
peptides result in suboptimal bioavailability of such biomolecule in 
nasal delivery upon intranasal delivery [26, 27]. Perhaps, 
overcoming these hurdles will maximize the clinical benefit of the 
system. Nowadays, the potential technique for chemotherapeutic 
delivery enhancement for CNS tumor targeting is by encapsulating 
the drug into nanoparticles and administer them through the 
intranasal route [28, 29]. Nanoparticles have owed several 
advantages of optimization of drug pharmacokinetics to the 
compromisation of the physiological barriers enhancing the drug 
concentration at the targeted site [30]. Nevertheless, nano-size 
features of different NPs boost their transcellular transport 
proficiency, optimizing the targeted therapy for specified brain-
tumors. Therefore, several NPs have been used as drug carrier 
vehicles for brain tumor targeting via nasal route [23, 31]. The 
review evaluates the clinical importance of brain tumor targeting 
through nasal administration and its therapeutic benefit over 
conventional delivery systems.  
Brain tumors 
Brain tumors have different classification types, most prominently; 
they have been classified into primary and secondary brain tumors 
[fig. 1]. 
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Fig. 1: Classification of brain cancer 
 
The primary tumors were categorized according to their 
originating tissues; gliomas, primitive, vestibular neuro-
ectodermal, and pituitary adenoma. In contrast, the secondary 
tumors were characterized as metastatic tumors [32, 33]. The 
gliomas initiated from glial cells are the predominant types of CNS 
tumors that are associated with poor prognosis, including 
glioblastoma multiform (GBMs) which accounted for 81% of all 
brain tumors, astrocytoma (AS) oligodendrogliomas (OAs), among 
others. On the other hand, in 2004, the World Health Organization 
WHO further classified the CNS tumors based on their 
histopathological parameters using a four-point grading scale [ I-
IV] [34] as illustrated in table 1. 
  
Table 1: WHO grading of brain tumors 
WHO  Descriptive features Members  Criteria  Ref. 
Grade I Slow proliferating non-malignant tumours, 
with high survival chances.  
angiocentric glioma, pilocytic astrocytoma, 
and subependymal giant cell astrocytoma 
Nil [35] 
 
Grade II Slow proliferating tumours with a high-
grade, recurrent tendency, they may be 
malignant or non-malignant.  
chordoid glioma of the third ventricle, low-
grade diffuse astrocytoma, and cellular 
and clear cell ependymoma 
Cytological atypia (atypical cell) 
Grade III Malignant tumours that might reoccur as a 
high-grade tumour 
anaplastic astrocytoma, and anaplastic 
oligoastrocytoma 
Mitotic and activity anaplasia  
Grade IV Proliferate rapidly with high malignancy Glioblastoma multiform GBM Mitotic, activity anaplasia with 
necrosis, and microvascular 
proliferation 
 
Rate limiting barriers for chemotherapeutic delivery to CNS  
Both blood-brain and blood tumor barriers are known as inherent 
barriers that limit the absorption and transport of molecules 
between systemic circulation and the brain, which significantly 
reduces the bioavailability of pharmacological agents, reducing their 
clinical efficacy in treating various brain infections and disorders. As 
shown in [fig. 2]. 
 
 
Fig. 2: Blood-brain and blood-tumor barrier 
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The blood-brain barrier (BBB) 
Anatomically, the BBB consists of an inner endothelial layer 
containing several tight junctions composed of claudin and occludin 
layers encapsulated with the basal membrane and further encircled 
by the Astrocyte. Pericyte is wrapped in the basal membrane 
between the outer Astrocyte and the endothelial layer. However, the 
tight junctions are solely responsible for limiting the paracellular 
movement of substances across BBB. Whereas the basement 
membrane augments its protective effectiveness [36–39] However, 
BBB is highly selective in nature, allowing only specific molecules 
with unique physiochemical properties of tiny size (preferably 
“nano form”), the molecular weight of less than 400 Da, ionization of 
1.5 to 2.7 and intense hydrogen bonding. These features restrict the 
entrance of many drugs and bio-molecules into the brain [40-42]. 
Brain tumour barrier (BTB) 
The brain tumour barrier is a protective layer formed consequent of 
an anatomical and physiological alteration of BBB, because of the 
regeneration of new blood vessels that oxygenate the growing 
tumour through the loosed-tight junctions of the endothelial cells. 
These newly formed vessels had some tiny pores that prevented the 
permeation molecules, including hydrophilic ones [43–45]. The 
affected tissue triggers the release of Vascular Endothelial Growth 
Factor (VEGF) that facilitated the neoangiogenesis system allowing 
the tumour to metastases throughout the brain. As a result, these 
changes further limited the absorption of chemotherapy agents’ into 
the targeted brain tumour [46]. 
Blood cerebrospinal fluid barrier (BCB) 
Blood Cerebrospinal Fluid Barrier is the rate-limiting step for drugs 
and molecules absorption from the systemic circulation to CNS. 
Physiologically, the arrangement of choronoid plexus’ epithelium 
limits the molecular exchange from blood to CSF. Besides, the brain 
parenchymal cells formed an arachnoid membrane (double layer) 
between the pia and dura mater, guided by tight junctions that 
enhance the integrity of the BCB and serve as the drainage system of 
CSF. However, this barrier the second most preventive barrier after 
BBB that limits the drug permeation to CNS [47]. 
Mechanism of intranasal delivery of chemotherapeutic agents  
Studying the anatomy and physiology of the nose and associated nerves 
are essential for understanding the nose-to-brain delivery mechanisms, 
useful for developing the ideal formulation for brain targeting [48, 49]. 
Conversely, the nasal cavity is divided by the lateral and septal walls into 
two halves, that supplies sensory and olfactory nerves; in which the 
olfactory nerves extend to the brain [50]. In contrast, the sensory 
innervation consists of the mandibular, maxillary, and ophthalmic zones 
of the trigeminal nerve [51]. The entire nose consists of three regions, 
namely the respiratory, olfactory, and vestibular areas [52] Extension of 
the olfactory nerve ends in the olfactory bulb (chemosensory zone) 
where the drug’s maximum concentration can be found in the brain. 
Interestingly, the olfactory bulb is directly connected to the brain, 
enabling the intraneuronal transport of a particular compound to 
different parts of the brain. Moreover, the olfactory mucosa supplies the 
skull in close vicinity to CNS [53]. Unfortunately, the molecules are 
delivered through an olfactory nerve in a delay pattern. Alternatively, the 
molecules infiltrate the pre-neural compartment of the cranial nerves 
and flow to the CSF, from where it permeates to different parts of the 
brain [54]. However, the trigeminal, olfactory and respiratory epithelia 
permit therapeutics to distribute to other brain sections. [55] S. Yadav et 
al. found the intranasal administration of cyclosporine A (CSA) 
nanoemulsion riches the brain at higher concentrations. It was identified 
to have reached the brain through the olfactory bulb, hindbrain, and 
midbrain (via olfactory epithelium) through CSF [56]. R. G. Thorne et al. 
investigated the rat’s CNS pathways involved in delivering insulin-like 
growth factor-1 (IGF-I) via intranasal route; the researchers identified 
the two significant ways through which administered insulin [125
 
I] 
distributed and concentrated in the rats’ CNS and CSF. The “peripheral 
olfactory system” a system that links the nasal stream, olfactory bulbs, 
and anterior-brain portion. Whereas the “peripheral trigeminal system” 
channels nasal passage to brain steam and CSF. According to the authors’ 
report, intravenous administration of [125I] to another group revealed 
similar results with that of intranasal but showed lesser CNS 
concentration than an intranasal pathway [57]. Shinde et al. investigated 
the potential for nose-to-brain delivery of atomoxetine (ATX) 
encapsulated in liposomes using in vivo rat model experiments. 
Following a gamma scintigraphy examination, the result indicated a 
significant distribution of the drug in the CNS [58]. Therefore, good 
pharmacokinetics and physicochemical parameters of the drug 
determine its suitability for intranasal administration; usually, highly 
lipophilic unionized drugs that have low molecular weight are the 
desirable candidates for intranasal administration and hence could pass 
BBB through all these pathways [59]. As illustrated in [fig. 3]. 
 
Fig. 3: Mechanism of intranasal delivery of chemotherapeutics 
 
Nanocarriers use for tumor targeting via a nose-to-brain 
delivery system  
Nanocarriers transport the chemotherapeutic agents crossing BBB 
via several mechanisms, and they sustainably release the drugs to 
the brain. However, the FDA approved liposomes and dendrimers as 
a nanocarrier to deliver pharmacological agents to the brain. They 
have been widely used for targeting different types of brain disease 
through surface modification with other polymers and proteins [60, 
30]. We summarized the literature of these in [table 2] 
Preclinical studies  
In vitro trials 
Several studies have been carried out on the intranasal delivery of 
chemotherapeutics amongst Jeffrey J, et al.; demonstrated an in vitro 
experiment on rodents and primates models. The author examined 
the drug distribution in the rats’ perivascular space (PVS) and 
internal cerebral vessels using fluorescence imaging techniques, and 
the comparative study showed that the intranasal administration of 
the drug owed to have high distribution then intravenous 
administration. Therefore, the result indicated the potentiality of the 
intranasal route as an alternative way of delivering therapeutics for 
disease CNS targeting [61]. Khan A prepared and administered 
Temozolomide chitosan-nano-formulation using the Clone-6 (C6) 
glioma cell line of Wister rate via intranasal route. A 
histopathological examination at the end of the study has revealed 
the high delivery efficiency due to the mucosal effect from the 
chitosan-nanogel that sustained drug release. Moreover, the drug 
found to have attained the optimal concentration in the brain  [1].  
Angel T. Alex, et al.; evaluated the permeation efficiency of the 
antineoplastic drug (carboplatin), the permeation of both 
Carboplatin-loaded nanoparticle (CP-NPs) and pure carboplatin 
formulation was determined using in situ, in vitro, and ex vivo 
evaluation studies. In an ex vivo study, the authors isolated the new 
mucosal cell line of sheep and tested the two formulations; the study 
indicated that the CP-NPs have higher permeation efficiency than 
the pure formulation. Likewise, the in vitro study was conducted 
using the CP-NPs formulations, one containing higher and the other 
holding a lower polymer concentration. After 72 h of administration 
to 96-growing human glioblastoma cells, the result indicated the 
rapid, followed by sustained release pattern in both formulations. 
Although the formulation that contained the lower polymer 
concentration has shown to release faster, this demonstrated the 
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importance of using fewer polymers in such nano-formulations. 
However, the in situ evaluation has shown better nasal permeation 
in CP-NPs then the pure formulation. Overall, the Carboplatin-loaded 
nanoparticle (CP-NPs) could be a breakthrough for targeting brain 
tumors using intranasal administration [62]. Kanazawa, T., et al.; 
evaluated the safety and intranasal delivery efficiency of small 
interfering (siRNA) incorporated with modified block co-polymers-
Tat nano micelles using rat modal. The in vitro study on glioma C6 
cell-lines revealed high tumor inhibition upon intranasal delivery 
than intravenously injected formulation. Therefore, the author 
concluded that nose to brain rout is the most suitable means of 
targeting CNS disorders [63]. Maha N et al. formulated the intranasal 
Hyaluronic acid-based nanoemulsions of resveratrol and curcumin. 
The study shows the drug attained high concentration in the rats’ 
CNS due to the mucoadhesive nature and BBB permeation ability in 
the nasal passage [64]. Co-administration of acetazolamide with 5-
fluorouracil via intranasal and intravenous routes was evaluated by 
Author links open overlay panel T. Shingaki, et al. The concomitant 
administration through nose-to-brain route was found to have 
enhanced the drug concentration to 104% and 46% against 
intravenous administration of 5-uracil alone [65]. The study 
conducted by Hee-Yeon, et al.; showed a significant increase in 
temozolomide’s anti-tumour activity (TMZ) after intranasal delivery 
to the rats bearing TMZ-resistant malignant gliomas. This means 
that temozolomide (TMZ) intranasal delivery could overcome the 
resistivity of oral TMZ-resistant malignant gliomas [66]. 
In vivo trials  
J. H. Azambuja et al. administered siRNA-nanoemulsion intranasally 
to the Glioblastoma-induced Wister rats; the study’s result showed a 
60% reduction of glioblastoma tumor on the tested rat [67]. T. 
Sakane et al., evaluated the perfusion of 5-fluorouracil (5FU) in the 
rats’ CSF using in vivo models of wister rats. The authors compared 
the intranasal and intravenous drug concentration in the CSF. The 
study result indicated that the drug’s high concentration reaches the 
CNS via CSF upon intranasal delivery than intravenous [65]. Luxiang, 
et al., conducted an in vivo evaluation of the efficiency of intranasal 
administration. The authors prepared and administered tyrosine 
kinase nanoparticles intranasally to glioma-induced rats. Upon 
examination, the study results indicated a maximum possible 
reduction in tumour size by facilitating the apoptosis rate, which is 
then observed in other preparation [68]. M. Colombo et al. evaluated 
the intranasal delivery of kaempferol-loaded nanoformulation and 
mucoadhesive nanosuspension using in vivo rat model. 
Histopathological investigation of the rats treated with both 
formulations has shown the significant reduction in the size of 
glioma cells. However, kaempferol nanoemulsion induced apoptosis 
largely than mucoadhesive nanosuspension [69]. E. Sekerdag, et al. 
compared the anti-glioma efficacy of 500 μM PEGlycated-
farnesylthiosalicylic acid (FTA) on Wister rats for ten days 
intravenous and intranasal administration. After the post-treatment 
examination, the Nuclear Magnetic Resonance Imaging indicated the 
55.7% reduction in tumor size. According to the study, there is no 
difference observed upon administering FTA via the intranasal or 
intravenous route. Matthias Van et al. encapsulated the small 
interfering RNA (siRNA) in chitosan nanoparticles and administered 
it into Glioblastoma-induced mouse intranasally. The author treated 
the mouse with the prepared formulation for days 5, 8, 12, and 15. 
However, the immunofluorescence test performed on the 5the day 
post-treatment showed a significant reduction in tumor size. The 
author further observed high concentration of drug in olfactory 
bulbus upon in vitro intranasal delivery via the olfactory pathway 
(from where the drug possibly distributes directly to the CNS) [70]. 
Darshana S. et al. administered both pure and Polylactic Acid (PLA) 
suspended nanoparticles of methotrexate via the intranasal route of 
two sub-grouped mice, each containing six members. The first group 
was treated with pure methotrexate has shown low bioavailability 
because the drug is highly hydrophilic in nature; consequently, it 
cannot cross BBB. On the other hand, the second group treated with 
PLA-methotrexate NPs has shown significant CNS concentration in 
both in vitro and in vivo evaluation after the pharmacokinetics 
evaluation. This is because the Polylactic Acid nanosuspension has 
the sol-gel-sol property that increases MTX’s mucosal residence 
time; hence, the BBB penetration and CNS distribution. Lastly, the 
cytotoxic evaluation has shown no difference in toxicity between 
both the study participants. However, the authors proposed 
thermosensitive nanoformulation to be a gold standard for the 
formulation of antineoplastic drugs intended to target CNS tumors 
through the nose-to-brain route. [71] A. Mangraviti, et al. have 
developed the polymeric nanoparticles incorporated with plasmid 
DNA to transfect “Human adipose-derived mesenchymal stem cells” 
(hAMSCs) through the intranasal route of glioma infected rats, as an 
alternative to viral transduction system. The in vitro evaluation 
revealed the significant reduction in glioma cells size more 
efficiently than the usual viral transduction method. While the in 
vivo experiment has indicated the possibility of high viability among 
the glioma bearing rats  [72]. Hiroyuki Taki, et al. evaluated the anti-
tumour and safety effect of camptothecin (CPT)-nano-micelles on 
intranasal administration using glioma infected rats. The in vivo 
investigation revealed evidence of tumour-shrinking and high 
viability chances on the treated rats. The author established the 
safety of the formulation at a high dose of 2 mmol/ml [73]. 
According to the sun et al. report, the CNS concentration of 
Methotrexate (MTX) encapsulated in chitosan microspheres was 
determined to be 118% upon intranasal administration to healthy 
Wister rats. While it was remained undetected when administered 
intravenously. [74] The study conducted by Pineda JR, et al.; proved 
the effectiveness of intranasal infusion of Temozolomide (TMZ) as 
anti-glioblastoma in nude mice. After the drug administration 3times 
a week for two weeks, a remarkable reduction in tumor size without 
alteration in the mice’s sense of smell was observed [75]. 
Clinical studies for intranasal brain tumor targeting 
DA Fonseca et al. performed a clinical evaluation for the 
effectiveness of intranasal administration of “perillyl alcohol” (POH) 
on 152, 26, and 5 different patients with a primary glioblastoma 
GBM, astrocytoma grade III AA and anaplastic oligodendroglioma 
AO, respectively. The drug was intranasally administered to the 
patients 4 times daily, initiating a minimal dose of 66.7 mg/dose, 
and titrated to 533.6 mg/day. The study outcome after 4 y of the 
study indicated a favourable prognosis among the tested patients. 
However, 19% of them have been clinically under remission. 
Although 95% of the patients have developed rare nasal bleeding 
and soreness [76]. C. Fonseca, et al. conducted a phase I/II clinical 
trial to access the safety profile of Perillyl alcohol (POH) on patients 
with relapsed malignant glioma. The author was administered the 
intranasal dose of 0.3% vol/vol containing 55 mg POH 4times daily 
and consecutively to 37 patients who had sub-grouped into 29 with 
Glioblastoma, 3 with anaplastic oligodendroglioma and 5 with 
astrocytoma grade III, for the period of 6 mo. Upon completing the 
cohort study, the preliminary result indicated the safety, reliability, 
and non-invasive anti-tumor efficacy of POH. Clovis Fonseca, et al., 
had performed a clinical analysis on 67 patients with brain tumors 
the study evaluated the effectiveness of intranasal chemotherapy 
with Perillyl alcohol (POH) among glioma patients. The relationship 
between tumor size, localization, and relative treatment prognosis 
has been observed. Throughout the study period, the patients were 
categorized into some groups, in which 52, 10, and 5 patients 
bearing GBM, AA, and OA were recruited, respectively. A daily dose 
of 440 mg POH was maintained among the recruited patients. The 
author observed the longer survival chances and the promising 
clinical prognosis among the patients bearing recurrent malignant 
glioma, while those having lobar localization and peritumoral 
oedema have shown poor prognosis and low survival chances. 
Therefore, the study indicated the safety and tolerability of non-
invasive chemotherapy and evident the definite relationship 
between the tumor localization and clinical prognosis among glioma 
patients [78]. Clovis O. et al. the study on 62-year-old anaplastic 
oligodendroglioma patients revealed the notable reduction in tumor 
proliferation following the four times daily administration of l 0.3% 
POH intranasally [79]. However, the Brazil trial further affirmed the 
clinical safety, tolerance, and efficacy of intranasal POH, in a study 
that recruited 37 recurrent malignant glioma-bearing patients; these 
patients were treated with four times daily intranasal 0.3% POH for 
several days [80]. Chen TC et al. evaluated the safety and anti-tumor 
activity of POH in a clinical trial phase I/II among the patients with 
recurrent Glioblastoma. The patient has received 4-times daily 
intranasal POH for 6months; the trial evidenced the maximum 
shrinkage in the bearing patients’ tumor size with no toxicity and 
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unwanted side effect [81]. Juliana et al. studied the clinical 
implication of POH's concomitant administration and ketotic diet 
among 32 patients with recurrent Glioblastoma. After four times 
daily intranasal administration of POH, 17 with ketotic and 15 
without ketotic diet for a period of 3 month. Subsequent clinical 
investigation of the recruited patients, most of the patients who 
received the concomitant chemotherapy of POH with ketotic diet, 
shows significant tumor inhibition with no toxicity [82]. 
 
Table 2: Nanocarriers use for tumor targeting via the nose-to-brain delivery system 






Liposomes delivered the drug to the 
brain by permeating across the 
endothelial cells via endocytosis 
bi-layered, phospholipids that 
can entrap both hydrophilic and 
hydrophobic drugs and it 
possessed different surface 
charges 
Expensiveness, low 
drug loading capacity, 
and long term stability 
[83] 
Solid lipid  spherical in 
shape 1 and 
1000 nm 
It can permeate through the tight-
junctions of the endothelium via a 
transcellular pathway and pass 
across the BBB  
High drug loading efficiency, 
control releasing overcome the 
effect of mucociliary clearance 
and nasal degradation 
High water content (70 
to 99.9)%, Undesired 
drug load, leakage 
during storage  
[84] 




Polymeric NPs lodges the 
chemotherapeutic drug in the brain 
through passive or active 
transportation  
Higher polydispersity index, 
stability, biocompatible 
biodegradable non-toxic, non-
immunogenic and Inexpensive 
Clinical application is 
limited by uncertain 
toxicity  
[85] 
Nanoemulsion  globular size Improve mucosal absorption and 
overcome nasal mucociliary 
clearance  
Highly lipophilic, and 
permeation, low spherical size,  
Unavailability of 
intranasal product,  
[86] 
Chitosan  The increase in temperature enhances 
the gel formation and positive charges 
of chitosan interact with the negative 
charge of the mucosa that results in 
excellent retention and paracellularly 
cross the tight junctions of epithelial 
cells of BBB 




preparation, low toxicity, high 
stability and CNS delivery 





globular shape.  
The penetration efficiency of 
dendrimers potentiates by 
conjugation with transferrin, D-
glucosamine, leptin, and lactoferrin. 
The release depends on the PH and 
ionic strength of the media. 
Undergo compositional changes 
in response to the 
environmental condition, wide 






It is no gainsaying that brain cancer is a severe disease characterized 
by an inferior clinical prognosis. There are overall limited survival 
chances for brain cancer patients perhaps;, the patients bearing 
Glioblastoma multiform (GBM) are more clinically affected since 
their survival chances are no longer than 15 mo. Nevertheless, the 
optimum concentration of active drugs at the brain’s targeted site is 
a prerequisite for effectively managing the disease or disorder. 
Unfortunately, several anatomical and physiological barriers need to 
be overcome before the therapeutic agent could reach the brain. 
Most importantly, blood-brain (BBB), blood tumor barriers (BTB), 
and blood-cerebrospinal fluid barrier BCB. The choice of the suitable 
route of administering such drugs became very challenging; the oral, 
intravenous, and intrathecal routes have failed to provide the 
desired bioavailability. However, the non-invasive course for 
delivering chemotherapeutics to the brain to target various CNS 
tumors needs to be studied. The nose-to brain delivery was an 
alternative route for delivering anticancer drugs to CNS, being non-
invasive and highly efficient in bypassing the blood-brain and brain 
tumor barriers while limiting the systemic side effects. 
Although the intranasal delivery mechanism is not well understood, 
several investigations have demonstrated the drug to have reached 
the brain mainly through the olfactory and trigeminal nerves. 
However, incorporating nanoparticle and materials in the drug 
formulations has further enhanced the drug permeation across the 
BBB via the nose-to-brain route. Nevertheless, an extensive study on 
brain tumor targeting via the nose to brain rout will provide 
sufficient knowledge to aid the drug development and therapeutic 
outcomes of devastating brain tumors and other disorders. 
Therefore, nose-to-brain delivery of chemotherapeutics serves as 
the breakthrough for bypassing the effect of BBB, BTB, and CSF 
barriers. For that reason, designing the chemotherapeutics agents in 
the form of inhalational nanoformulation will enhance the clinical 
prognosis of CNS tumors and the patients’ quality of life.  
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